Vaccine Evaluation
Streamlining vaccine success
Developing vaccines hinges on a meticulous understanding of the immune system’s response to candidate antigens. Our vaccine evaluation solutions offer researchers a comprehensive toolbox to dissect intricate immunogenic pathways triggered by their vaccine candidates. By providing granular insights across diverse assays and models, we empower you to optimize your vaccine’s efficacy and safety profile, ensuring its real-world effectiveness in protecting individuals and communities.
- DC vaccine production
- Immunogenicity of Neo-antigens
- Memory T cell subsets after immunization
- Splenocyte stimulation assay (immunogenicity of IL-2 and IFN-gama via Elispot)
- Splenocyte stimulation assay (immunogenicity of IL-2 and IFN-gama release by FACS)
- In Vivo study of vaccine Immunogenicity
MODELS / SERVICES
Committed to quality:
- FDA part 11 compliant
- Animal studies strictly follow AAALAC and ILAC guidelines
- Electronically managed, traceable research data
- Rigorous adherence to international GLP and QA best practices
- Clients have real-time remote monitoring of studies
Want your scientific discoveries to become treatments? PharmaLegacy’s the right partner for you.
Providing Better Data For Critical Oncology Pipeline Decisions
To advance a compound from discovery to clinical, or to halt its development, is a huge and costly decision. For the benefit of you and your company, and for the well-being of patients in need of treatment, that decision needs to be based on correct information.
Download our Integrated In Vitro Oncology Assays brochure and see why over 300 pharmaceutical companies, including many global leaders, trust PharmaLegacy for the unbiased, accurate information they need to make critical oncology pipeline decisions.
We’re ready when you are.
Tell us your pharmacology challenges.
